The estimated Net Worth of Jasbir Seehra is at least 14.8 百万$ dollars as of 8 April 2023. Dr Seehra owns over 4,000 units of Keros Therapeutics stock worth over 13,843,866$ and over the last 6 years he sold KROS stock worth over 0$. In addition, he makes 908,087$ as Pres、 CEO、 Treasurer、 & Director at Keros Therapeutics.
Dr has made over 3 trades of the Keros Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of KROS stock worth 1,920$ on 8 April 2023.
The largest trade he's ever made was buying 20,000 units of Keros Therapeutics stock on 13 April 2020 worth over 320,000$. On average, Dr trades about 2,071 units every 78 days since 2018. As of 8 April 2023 he still owns at least 252,856 units of Keros Therapeutics stock.
You can see the complete history of Dr Seehra stock trades at the bottom of the page.
Dr. Jasbir Seehra Ph.D. is the Pres, CEO, Treasurer, & Director at Keros Therapeutics.
As the Pres、 CEO、 Treasurer、 & Director of Keros Therapeutics, the total compensation of Dr D at Keros Therapeutics is 908,087$. There are no executives at Keros Therapeutics getting paid more.
Dr D is 65, he's been the Pres、 CEO、 Treasurer、 & Director of Keros Therapeutics since . There are no older and 4 younger executives at Keros Therapeutics.
Jasbir's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Keros Therapeutics have traded over 50,765,607$ worth of Keros Therapeutics stock and bought 2,504,088 units worth 46,191,339$ . The most active insiders traders include Ran Nussbaum、Carl L Gordon、Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of 3,312,649$. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth 11,002,500$.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics executives and other stock owners filed with the SEC include: